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Abstract
Anti-phospholipid syndrome (APS) is one of the main causes for recurrent miscarriages. The diagnosis of APS is based on the occurrence of clini-
cal symptoms such as thrombotic events or obstetric complications as well as the detection of antiphospholipid antibodies directed against β2-
glycoprotein I and cardiolipin, or a positive lupus anticoagulant assay. However, there is a subpopulation of patients with clinical symptoms of APS, 
but the lack of serological markers (seronegative APS). In addition, a large proportion of patients with unexplained recurrent miscarriages exist. 
These cases may be attributed, at least in part, to a seronegative APS. 
The presence of autoantibodies against annexins is potentially associated with APS. Here we used immunoassays and immunoblots to detect auto-
antibodies directed against annexin A1-5, and A8, respectively, in a patient with a seronegative APS and a history of six recurrent pregnancy losses 
and fulminant stroke. We found strong IgM isotype antibody reactivity directed against annexin A2 and annexin A8, and moderate to weak IgM 
isotype antibody reactivity directed against annexin A1, A3, and A5. Further studies will evaluate the diagnostic value of IgM isotype antibodies aga-
inst annexin A1-A5, and A8 for seronegative APS and recurrent miscarriages. 
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Anti-phospholipid syndrome (APS) is an autoim-
mune disorder that leads to a hypercoagulative 
state. Clinically this disorder is characterized by 
any thrombotic event and/or specific obstetric 
complications, for instance preterm delivery and 
recurrent miscarriages (1-3). Therefore, APS is one 
of the main causes for pregnancy failure. Besides 
clinical symptoms, the presence of persistent cir-
culating antiphospholipid antibodies (aPL) is used 
for the diagnosis of APS. Antiphospholipid anti-
bodies are a heterogeneous family of autoanti-
bodies against proteins binding to negatively 
charged phospholipids. They exert thrombogenic 
effects as they interfere with plasmatic compo-
nents of the coagulation cascade, promote plate-
let aggregation and induce a pro-inflammatory 
and pro-coagulant endothelial phenotype (4). The 
relevant diagnostic aPL are IgG or IgM isotype au-
toantibodies directed against β2-glycoprotein I 
(anti-β2GPI) and cardiolipin (aCL), usually com-
bined with the lupus anticoagulant (LA) functional 
assay. Patients with a “triple positivity” are thought 
to be at higher risk than those with single or dou-
ble positivity to develop vascular thrombosis, 
pregnancy morbidity, and recurrent events (5,6). 
The lupus anticoagulant test is the most predictive 
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value for venous and arterial thrombosis in pa-
tients with suspected APS (7), whereas a high in-
termethod variability for aCL assays exists. This ex-
plains the low utility of aCL testing (8). The diag-
nostic value of the major epitope of ß2GPI is still 
controversial discussed due to potential conforma-
tional changes during the immunoassay which 
may lead to epitope masking effects. Hence, there 
is no universal aPL- detection method (9). At pre-
sent the diagnosis of an APS requires the detec-
tion of at least one of the three aPL, i.e. IgG or IgM 
isotype autoantibodies directed against β2-
glycoprotein I (anti-β2GPI) and cardiolipin (aCL), or 
a positive lupus anticoagulant (LA) functional as-
say. In addition, the revised ‘Sapporo’ criteria pro-
vide important details about the titres (> 40 GPL or 
MPL or > 99th percentile for aCL and > 99th percen-
tile anti-β2GPI) of aPL and their persistence in time 
(presence on two or more occasions at least 12 
weeks apart) to reduce the probability of misdiag-
nosing APS in patients with thrombosis or preg-
nancy morbidity with transient or low titre aPL an-
tibodies (5). Moreover there is an emerging group 
of autoantibodies potentially associated with APS 
(10). These autoantibodies are directed against 
proteins involved in coagulation, or cell mem-
brane binding, but their clinical utility and diag-
nostic value remain unclear. This leads to a diag-
nostic gap in patients with clinical symptoms of an 
APS, but without evidence of established serologi-
cal markers (seronegative APS, SNAPS), and may 
have fatal consequences for the patients. 
Annexins (Anx) are a family of 12 highly conserved 
proteins characterized by their ability to bind 
phospholipids in a calcium dependent manner. 
Autoantibodies against annexins have been de-
scribed in different diseases and, by now, autoanti-
bodies against AnxA1, AnxA2, AnxA4, AnxA5 and 
AnxA11 have been detected in the serum of hu-
mans (11,12). Recently, it was shown that AnxA5 
self-assembles into 2D-arrays on membranes upon 
Ca2+ activation, and it has been suggested that 
AnxA5 competes with coagulation factors for 
phosphatidylserine binding to inhibit the activa-
tion of the coagulation cascade (13). This annexin 
is strongly expressed in the placenta (14) and by 
binding to negatively charged phospholipids at 
cell membranes (15) may be needed to maintain 
the placental integrity (16). Autoantibodies to 
AnxA5 have been proposed to be associated with 
the clinical features of APS, including thrombosis 
and recurrent miscarriages, and various research 
groups suggest autoantibodies against AnxA5 as 
additional serological criteria for APS (17). 
In this study, we investigated the presence of IgG 
and IgM isotype autoantibodies directed against 
AnxA1-A5, and AnxA8 in a patient with a history of 
six pregnancy losses and a fulminant stroke, but 
with no evidence of the established diagnostic an-
tibodies against β2GPI and aCL, or LA.
Materials and methods
Subject 
At the age of 30, the female patient was diagnosed 
with systemic lupus erythematodes (SLE). Clinical-
ly the patient showed symptoms of pleurisy and of 
a lupus nephritis. In addition, elevated levels of an-
ti-nuclear antibodies (ANA) and anti-double 
stranded DNA antibodies (dsDNA) were detected. 
The autoimmune disorder was managed with 125 
mg cyclosporine and 5 mg prednisolone. At the 
age of 34, the patient uttered the wish for preg-
nancy, but the patient suffered two early miscar-
riages. An evaluation of intrauterine abnormalities, 
transvaginal ultrasound scans and hysteroscopy 
gave no pathological changes. After the second 
miscarriage, the patient was furthermore tested 
for factor V-Leiden and prothrombin mutation, an-
tithrombin, protein C and protein S deficiency, 
pathological factor VIII and factor XII activity, for 
anti-paternal antibodies, and several times for IgG 
and IgM isotype autoantibodies against aCL, and 
LA. None of these investigations gave pathological 
results. The detection assay for anti-β2GPI autoan-
tibodies was not established at this time in our 
laboratory. Due to the clinical presentation, the 
patient has been diagnosed with seronegative 
APS. Therefore, an anticoagulative therapy with 
heparin was started after the second miscarriage, 
but the patient suffered three more early miscar-
riages. The gestational age of the miscarriages 
ranged from the 5th to 8th week of pregnancy. Af-
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ter the fifth miscarriage, the immunosuppressive 
therapy was changed to 5 mg prednisolone every 
second day, and the patient received an anticoag-
ulative and antiplatelet therapy with heparin and 
acetylsalicylic acid 100 mg/day. The patient had 
another miscarriage, but also delivered a healthy 
child at the age of 38 and of 41, respectively. As the 
patient was only clinical diagnosed with APS, the 
anticoagulative and antiplatelet medication was 
stopped after the second child birth. At the age of 
42, the patient suffered a fulminant stroke and 
presented a hemiparesis, hypoesthesia as well as 
an aphasia. Investigations gave no evidence of an 
embolic source, such as cardiac arrhythmia, cere-
bral vasculitis or actual autoimmune activity of the 
SLE. 
Blood samples
Two blood samples (leftover samples) were taken 
into 4.7 mL serum monovettes (Sarstedt, Nümbre-
cht, Germany) and centrifuged at 3000 x g for 10 
minutes, and analysed by immunoblot and immu-
noassay. The first sample was taken immediately 
after stroke; the second sample was picked 20 
weeks later. 
Recombinant expression and purification of 
AnxA1-A5 and AnxA8 
Recombinant annexins were expressed in bacteria 
(BL21) and purified by affinity chromatography us-
ing glutathione Sepharose 4B (GE Healthcare, 
Uppsala, Sweden). The glutathione S-transferase-
tag was removed by cleavage with Factor Xa ac-
cording to the manufacturer’s protocol (Merck, 
Darmstadt, Germany). Purified annexins were dia-
lyzed against 20 mM Hepes, 100 mM NaCl, pH 7.4. 
Endotoxin Removal Gel (Thermo Scientific, Rock-
ford, USA) containing immobilized polymixin B 
was used in a column format to affinity-purify the 
annexins as described previously (15). 
Sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and immunoblot - 1 µg of 
recombinant annexin A1-A5, or A8, respectively, 
was separated on a 4–12% Bis-Tris gel (NuPAGE, 
Carlsbad, USA). For immunoblotting, the proteins 
were transferred to a polyvinylidene fluoride 
(PVDF) membrane (0.45 μm, Invitrogen, Carslbad, 
USA). Membranes were blocked in Tris buffered sa-
line (TBS) with 0.05% Tween and 5% milk powder, 
incubated with patient’s serum 1:100 in TBS with 
0.05% Tween and 5% milk powder, and finally in-
cubated and with horseradish peroxidase (HRP)-
conjugated goat anti-human IgG or anti-human 
IgM isotype antibodies (Invitrogen, Camarillo, 
USA) in TBS with 0.05% Tween and 5% milk pow-
der. Membranes were treated with electrochemi-
luminescence according to the manufacturer’s in-
structions (GE Healthcare, Little Chalfont, UK), and 
bands detected with specific antibodies were visu-
alized on Hyperfilm (GE Healthcare, Little Chalfont, 
UK). 
Densitometric analyses of immunoblots were per-
formed using ImageJ software. Therefore, pixel 
values were transformed into relative signal inten-
sities of selected areas (18).
Enzyme-linked immunosorbent assay (ELISA) 
Relative annexin autoantibody concentrations 
were determined by non-commercial ELISA. 
Therefore, 2 µg recombinant annexin/well was 
coated overnight at 4 °C on a 96-well plate (Nunc, 
Roskile, Denmark). The wells were subsequently 
incubated for 1 hour with the patient’s serum 
(1:50) and HRP-conjugated goat anti-human IgM 
isotype antiserum (Invitrogen, Camarillo, USA). Sig-
nals were visualized by incubation with tetrameth-
ylbenzidine (TMB) (Sigma-Aldrich, St-Louis, USA). 
Each ELISA was assayed in duplicate and per-
formed three times. Albumin (Sigma, St. Louis, 
USA) was used as negative control. The optical 
density (OD) was measured at 450 nm. The OD 
correlates with antibody concentrations or anti-
body reactivity’s, respectively, and fold change of 
antibody concentration was compared to the low-
est value or control. The signal of buffer only was 
defined as cut off value. 
Biochemistry tests
Routine laboratory biochemistry tests (serum cre-
atinine, C-reactive protein) were run on a Roche 
Cobas C702 automated clinical chemistry analyser 
(Roche Diagnostics, Mannheim, Germany) with 
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original Roche reagents. C3- and C4- complement 
factors were determined on a BNProSpec analyser 
(Siemens Healthcare Diagnostics, Marburg, Ger-
many) with original Siemens reagents. A blood 
count was performed on a Sysmex XE-5000 ana-
lyser (Sysmex Corporation, Kobe, Japan). The 
erythrocyte sedimentation rate was measured on 
the automated ESR systems Sediplus S 2000 with 
S-Sedivettes (Sarstedt, Nümbrecht, Germany). LA 
functional assay was performed on a BCS analyser 
with Dade Actin FS or FSL Activated PTT Reagent 
(Siemens Healthcare Diagnostics, Marburg, Ger-
many). IgG and IgM isotype antibodies against 
ß2GPI were determined with a Quanta ß2-GPI IgG 
or IgM-ELISA (Inova Diagnostics, San Diego, USA) 
on a DSX-ELISA-System (Dynex technologies, 
Chantilly, USA). Antibodies against CL were meas-
ured with an anti-cardiolipin IgG- or IgM-ELISA on 
an Euroimmun-Analyser I (Euroimmun, Lübeck, 
Germany). Antinuclear antibodies (ANA) were de-
tected using the indirect immunofluorescence 
method on HEp-2 cells with a commercially availa-
ble diagnostic kit (Euroimmun, Lübeck, Germany) 
according to the manufacturer’s instructions. Anti-
double-stranded DNA (anti-dsDNA) IgG isotype 
antibodies in serum were measured with the anti-
dsDNA-NcX-ELISA (IgG) on an Euroimmun-Analys-
er I (Euroimmun, Lübeck, Germany).
Results 
LA functional assay and IgG and IgM isotype anti-
bodies against ß2GPI or CL were determined im-
mediately after stroke. IgG and IgM isotype anti-
bodies against ß2GPI or CL were additionally test-
ed 9 months later. aPL could not be detected and 
there was no laboratory evidence for APS before 
and after the clinical event. In addition, similar 
ANA and anti-dsDNA antibodies, and serum creati-
nine levels were detected before and after stroke. 
ANA titre level was 1:1000, anti-dsDNA antibodies 
were negative, and serum creatinine concentra-
tion was around 130 μmol/L. C3- and C4-comple-
ment factor, CRP, leukocytes and platelets were in 
the normal range. Erythrocyte sedimentation rate 
was 30 mm/hour (normal: < 14 mm/hour). In addi-
tion, the patient’s serum was investigated by im-
munoblot for the presence of annexin autoanti-
bodies. We could identify strong reactivity of IgM 
isotype autoantibodies directed against AnxA2 
and AnxA8, medium to low reactivity of IgM iso-
type autoantibodies against AnxA1, AnxA3, and 
AnxA5, and no antibody reactivity against AnxA4 
and albumin. Antibodies of IgG isotype only 
showed a slight reactivity against AnxA1 and 
AnxA5 (Figure 1). The relative signal intensity of 
the immunoblot was evaluated by ImageJ (Figure 
3) (18).
Furthermore, we verified the results of the immu-
noblot by ELISA. In accordance to the results of the 
immunoblot, we found high and persistent IgM 
isotype antibody reactivity directed against AnxA2 
and AnxA8, and medium IgM isotype antibody re-
activity directed against AnxA1 and AnxA3 (Figure 
2).
Discussion 
Here, we report the case of a woman diagnosed 
with seronegative APS and a history of six preg-
nancy losses and fulminant stroke, with no evi-
dence of the diagnostic relevant aPL antibodies, 
but with persisting high IgM isotype autoantibod-
ies reactivity against AnxA2 and AnxA8. 
As mentioned above, there is a growing number 
of aPL that may be involved in thrombosis or preg-
nancy morbidity, but only the three best investi-
gated aPLs (aCL, aβ2GPI, and LA) were included in 
the laboratory criteria of an APS. This leads to a di-
agnostic gap in patients with clinical symptoms of 
an APS, but without evidence of established sero-
logical markers. Since APS is a treatable cause of 
recurrent miscarriages, it is important to improve 
the identification of patients with a seronegative 
APS. Recently, autoantibodies against AnxA5 were 
found to be present in up to 17% of obstetric man-
ifestations of APS cases, being the only serologic 
parameter significantly associated with miscar-
riage (19). However, due to inconsistent results 
among studies (8) the clinical correlation of au-
toantibodies against AnxA5 is still controversial 
discussed. Here, we detected moderate reactivity 
of IgM isotype antibodies against AnxA5, but we 
Biochemia Medica 2016;26(2):272–8  http://dx.doi.org/10.11613/BM.2016.032 
276
Scholz P. et al. Seronegative APS and annexin antibodies 
Figure 1. Immunoblot.
Serum of the patient was analysed immediately after stroke by Sodium dodecyl sulphate polyacrylamide gel electrophoresis follow-
ing ponceau staining (upper row) and immunoblot (lower row) under reducing (+SH) and non-reducing conditions (-SH) for IgM and 
IgG isotype autoantibodies directed against annexin A1-A5 (A1-A5), and annexin A8 (A8). We found high IgM isotype autoantibody 
reactivity directed against annexin A2 and annexin A8, and almost no IgG isotype autoantibody reactivity against annexins. Albumin 
(Alb.) was used as negative control. kDa - kilo Dalton.
found considerably high reactivity of IgM isotype 
autoantibodies against AnxA2 and AnxA8 in the 
serum of our seronegative APS patient that suf-
fered six miscarriages. 
It was shown that AnxA2 interacts with β2GPI and 
Toll-like receptor 4 (TLR4) in a signalling complex 
leading to an inflammatory and pro-coagulant 
phenotype on endothelial cells (20,21). Autoanti-
bodies against AnxA2 were detected in APS pa-
tients, but the diagnostic sensitivity of the AnxA2 
test is quite low, and AnxA2 autoantibodies were 
also detected in patients suffering from other au-
toimmune conditions lowering also the diagnostic 
specificity (8). AnxA8 is one of the least character-
ized members of the annexin family. AnxA8 was 
described as an inhibitor of phospholipase A2 and 
as a blood coagulation factor (22). As yet, there are 
no studies that have investigated AnxA8 antibod-
ies in autoimmune conditions or other diseases. 
Here, we could show for the first time the pres-
ence of IgM isotype autoantibodies against AnxA2 
and AnxA8 in a patient with seronegative APS.
There are various studies that investigate autoanti-
bodies against annexin in the course of APS, for 
example autoantibodies against AnxA5 or AnxA2, 
but no study has investigated the presence of dif-
ferent annexin autoantibodies in a patient with 
APS. Furthermore, most of the investigations focus 
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on IgG isotype autoantibodies. Three studies in-
vestigated associations between circulating IgM 
isotype autoantibodies against AnxA5 and obstet-
ric complications and interestingly in one study, 
IgM isotype autoantibodies against AnxA5 were 
found to be stronger associated with obstetric 
complications than IgG isotype autoantibodies 
(23). In this patient, we found high IgM isotype an-
tibody reactivity directed against Anx2 and Anx8. 
IgM isotype antibodies appear early in the course 
of an infection and there are various studies re-
porting infect associated transient autoantibodies 
(24,25). Infect associated autoantibodies are the 
reason why repeated serological analysis of aPL 
within 12 weeks are mandatory in the diagnostic 
criteria of APS. In this patient, we investigated the 
persistence of the circulating annexin antibodies 
and could demonstrate persisting IgM isotype au-
toantibodies against AnxA2 and AnxA8 in con-
stant titres over a period of 20 weeks. 
In the last years, different technical approaches for 
the detection of aPL have been developed. These 
techniques comprise solid phase immunoassays 
(e.g. ELISA), multiline dot assays (dot blot) and thin 
layer chromatography (8). Most of the studies were 
performed with solid phase assays, e.g. ELISAs. Of 
course, ELISAs allow the quantification of the corre-
sponding antibody, but lacks of specificity. To over-
come this restriction, we used both, ELISA as well as 
immunoblot analysis, to verify antibodies against 
AnxA2 and AnxA8 in the patient’s serum. In this pa-
tient, we therefore can exclude unspecific cross-re-
activity of the detected annexin autoantibodies. 
In conclusion, we describe for the first time the 
presence of autoantibodies directed against differ-
ent annexins and persistent IgM isotype autoanti-
body reactivity directed against AnxA2 and AnxA8 
in a patient with seronegative APS who suffered six 
miscarriages. Further studies in additional patients 
are needed to evaluate and proof that the detec-
tion of different annexin autoantibodies elevate the 
diagnostic sensitivity and specificity to bridge the 
diagnostic gap for patients with seronegative APS 
and unexplained recurrent miscarriages.
Potential conflict of interest
None declared.
Figure 2. Anti-annexin enzyme-linked immunosorbent assay 
(ELISA).
Serum of the patient was analysed by ELISA for IgM isotype au-
toantibodies directed against annexin A1-A5 (A1-A5), and an-
nexin A8 (A8), immediately after stroke (dark columns) as well 
as 20 weeks apart (light columns). We found high IgM isotype 
autoantibody reactivity directed against annexin A2 and an-
nexin A8, and medium IgM isotype autoantibody reactivity di-
rected against annexin A1 and annexin A3. Each ELISA was as-
sayed in duplicate and performed three times. The results are 
depicted as optical density (OD) values at 450 nm. Error bars 
represents the standard deviation. Albumin (Alb.) was used as 
negative control.






Figure 3. Transformation of pixel values into relative signal in-
tensities (in percent, %) of the anti-IgM immunoblot (+SH) with 
Image J. 
The relative signal intensities of annexin A1-A5 (A1-A5), and an-
nexin A8 (A8) were calculated using Image J software. Com-
parison of the relative signal intensities of the immunoblot and 
the enzyme-linked immunosorbent assay yielded consistent 
results, with strongest IgM isotype autoantibody reactivity di-
rected against annexin A2 and annexin A8.
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